Hemostemix (CVE:HEM) Stock Price Down 16.7% – What’s Next?

Hemostemix Inc. (CVE:HEM) shares were down 16.7% during mid-day trading on Tuesday . The stock traded as low as C$0.10 and last traded at C$0.10. Approximately 236,500 shares changed hands during trading, a decline of 15% from the average daily volume of 278,294 shares. The stock had previously closed at C$0.12.

Hemostemix Trading Up 34.5 %

The stock has a market capitalization of C$16.99 million, a P/E ratio of -9.75 and a beta of 0.20. The company has a fifty day simple moving average of C$0.09 and a two-hundred day simple moving average of C$0.07.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.